Terns Pharmaceuticals To Present At 43Rd Annual J.P. Morgan Healthcare Conference

2025-01-08 04:16:23

(MENAFN- GlobeNewsWire - Nasdaq) FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the“Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare conference on January 15th, 2025 at 4:30 p.m. PT.

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at . A replay of the webcasts will be archived on Terns' website for at least 30 days following the presentations.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: .

Contacts for Terns

Investors
Justin Ng
...

Media
Jenna Urban
Berry & Company Public Relations
...

MENAFN08012025004107003653ID1109069913

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.